|
|
Profile
|
Delegates :
Kanae Gama |
|
Incorporated :
January 18 , 2018 |
Paid in Capital :
100 Million yen |
Employees :
32 人 |
Address :
26-1 Muraokahigashi 2-chome, Fujisawa-shi KANAGAWA
〒251-0012
|
TEL/FAX :
+81-466-96-0261 / |
URL：
https://www.fimecs.com/en/ |
Attachment :
|
Mission/Background :
FIMECS, Inc. is a drug discovery biotechnology company developing novel therapeutics based on Targeted Protein Degradation (TPD). Utilizing its proprietary RaPPIDS(TM) platform and unique E3 ligase binders, the company aims to create first-in-class medicines against previously undruggable targets. FIMECS actively collaborates with pharmaceutical companies and academic institutions to address significant unmet medical needs and deliver life-saving medicines worldwide. |
|
Technology & Business
|
FIMECS develops innovative therapeutics utilizing targeted protein degradation technology. Its proprietary RaPPIDS(TM) platform enables rapid discovery and optimization of degrader compounds against difficult biological targets. The company advances internal drug discovery programs while expanding collaborations with pharmaceutical companies and research organizations in oncology, immunology, and other disease areas.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
RaPPIDS(TM) Drug Discovery Platform
|
Service/Marketing
|
Proprietary platform for TPD drug discovery
|
Expand partnerships globally
|
IRAK-M Degrader Program
|
Preclinical
|
TPD program targeting IRAK-M
|
Clinical development
|
XIAP-related Discovery Program
|
Discovery
|
Small-molecule discovery program for XIAP
|
Advance discovery
|
|
|
|
|
|
|
|
|
|
Highlights
|
FIMECS is advancing research collaborations with Astellas Pharma on targeted protein degraders against multiple targets and has achieved multiple research milestones. FIMECS has also received notices of allowance for patents covering its IRAK-M degrader in Japan and other jurisdictions.
|
|
Alliance strategy
|
FIMECS is seeking strategic partnerships with pharmaceutical and biotech companies and academia in the field of targeted protein degradation. FIMECS current partnering opportunities include:
- Drug discovery collaborations using our proprietary RaPPIDS(TM) platform, including programs leveraging novel E3 ligases
- Licensing of TPD programs/assets
|
|
|